What R-Pharm does

R-Pharm is a Russian-headquartered, privately held pharmaceutical group founded in 2001 that operates as a vertically integrated developer, manufacturer, and distributor of pharmaceuticals, biologics, and medical equipment. The company operates 11 GMP-certified manufacturing plants across Russia (Moscow, Yaroslavl, Rostov, Kostroma, Zelenograd, Dubna), Germany (Illertissen), and Azerbaijan (Baku), with combined annual capacity exceeding 8 billion units of finished dosage forms and active pharmaceutical ingredients. Its proprietary biologics pipeline includes Olokizumab (Artlegia), an IL-6 inhibitor for rheumatoid arthritis that received international guideline recognition; Goflikicept (Arcerix), launched in 2024 as the first Russian drug for idiopathic recurrent pericarditis; and Ardaleva (ondelopran) for alcohol addiction. The pipeline contains 100+ medicines in development with 40+ active clinical trials spanning oncology, virology (HIV/hepatitis), immunology, autoimmune, cardiovascular, and orphan diseases.

The business operates four primary revenue streams: (1) pharmaceutical product sales to Russian government healthcare institutions and CIS markets via a 50+ regional office distribution network; (2) contract manufacturing and technology localization for global partners including Teva (Novoselki plant acquired 2021), Canon Medical Systems, Fujifilm, and Varian Medical Systems; (3) medical equipment distribution for radiology, radiotherapy, and laboratory diagnostics; and (4) R&D services including preclinical and clinical trials conducted with international research institutes. Strategic alliances include a 2017 10% equity investment by Japan's Mitsui & Co. (whose executive Yasuhiko Fujisaki became Deputy CEO in 2026), COVID-19 vaccine production for RDIF/Sputnik V, and clinical collaborations with AstraZeneca. The company holds the only Russian license to manufacture Varian linear accelerators for radiation therapy and is one of few Russian producers of monoclonal antibodies. Geographic reach spans 150+ countries via the German facility, with newer offices in San Diego (R&D), Hanoi (2022), and Turkey-focused partnerships (2024).

Name

R-Pharm

Legal name

R-Pharm Group

Website

https://r-pharm.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

R-Pharm is a privately held Russian-headquartered pharmaceutical group founded in 2001, operating 11 GMP-certified manufacturing plants across Russia, Germany, and Azerbaijan, developing and commercializing proprietary biologics (Olokizumab, Goflikicept), biosimilars, and medical equipment for government healthcare systems, CIS markets, and 150+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Biopharmaceutical development
• Medical equipment distribution
• Contract manufacturing services
• Clinical research services

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Products Sales: Sale of proprietary and licensed pharmaceutical products across therapeutic areas including oncology, virology, immunology, and cardiovascular diseases.
2. Contract Manufacturing: Localization of production for international pharmaceutical companies including technology transfer and license agreement manufacturing.
3. Medical Equipment Distribution: Distribution and localization of medical equipment including Canon Medical Systems, Fujifilm, Varian linear accelerators, and laboratory equipment from BD, Bio-Rad, Snibe, and others.
4. Research and Development Services: R&D services including preclinical and clinical trials conducted in partnership with international research institutes and pharmaceutical companies.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

R-Pharm researches, develops, manufactures, and distributes proprietary and licensed pharmaceutical products (oncology, antivirals, immunology, autoimmune, cardiovascular, rheumatology, diabetes/endocrinology, orphan diseases) plus biosimilars, original biologics, MRI contrast agents, and medical devices including radiotherapy linear accelerators. The company operates 11 GMP-certified manufacturing plants across Russia, Germany, and Azerbaijan, and conducts contract manufacturing, technology transfer, and R&D services for international pharmaceutical and medical equipment partners.

Product overview

R-Pharm is a Russian pharmaceutical company specializing in research, development, and production of pharmaceuticals, laboratory equipment, and medical devices. The product portfolio consists of multiple therapeutic categories including oncological drugs (antitumor agents, chemotherapy), antiviral medications (HIV, hepatitis, coronavirus), immunology/immunosuppressants, cardiovascular drugs, rheumatoid arthritis treatments, diabetes/endocrinology medications, and MRI contrast agents. The company operates multiple high-tech manufacturing plants across Russia and internationally, producing finished dosage forms, biotechnological substances, active pharmaceutical ingredients, and medical equipment. Key proprietary drugs include Olokizumab/Artlegia (IL-6 inhibitor for rheumatoid arthritis), Goflikicept/Arcerix (for pericarditis), and various antiviral medications.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncological Medications R-Pharm's portfolio of antitumor agents and chemotherapy drugs including Abiraterone, Palbociclib, Ibrutinib, Pembrolizumab, Bendamustine, Capecitabine, Dasatinib, Gefitinib, Imatinib, Lenalidomide, Lenvatinib, Pazopanib, Pemetrexed, Pomalidomide, Rituximab, Sorafenib, Temozolomide, Azacitidine, and Everolimus, sold to hospitals and oncology centers.
• Antiviral Medications Antiviral drugs for HIV therapy (Abacavir, Dolutegravir, Etravirine, Atazanavir, Emtricitabine, Efavirenz, Raltegravir, Saquinavir, Tenofovir), hepatitis treatments (Narlaprevir, Sofosbuvir, Daclatasvir), and coronavirus treatments (Favipiravir/Koronavir, Molnupiravir/Alario, Nirmatrelvir/Arpaxel, Remdesivir), supplied to hospitals and infectious disease centers.
• Artlegia (Olokizumab) Original biologic humanized monoclonal antibody that directly blocks inflammatory mediator Interleukin-6, developed for treatment of rheumatoid arthritis; included in international clinical recommendations for RA therapy.
• Arcerix (Goflikicept) Original hybrid protein that binds proinflammatory cytokines of the IL-1 family, developed for the treatment of idiopathic recurrent pericarditis; first such innovative drug launched in Russia.
• Ardaleva (Ondelopran) R-Pharm's drug for the treatment of alcohol addiction, developed and brought to market in 2022 as part of its expanding proprietary portfolio.
• Coronavir (Favipiravir) Antiviral drug based on favipiravir used for the treatment of COVID-19, brought to market in 2020 alongside diagnostic test systems.
• Immunology Medications Immunosuppressive and immunomodulatory drugs including Mycophenolic acid, Ibrutinib/Arbruviya, Tofacitinib/Kseltitsin, Lenalidomide, and Mycophenolate mofetil for autoimmune and transplant indications.
• Cardiovascular Medications Cardiovascular medications including Goflikicept/Arcerix (pericarditis), Apixaban/Domisaban (anticoagulant), Eltrombopag/Eltrombol, Fondaparinux sodium, Macitentan, Sotalol, Ticagrelor/Tikalizis, and Valsartan+sacubitril/Valsarepin for heart and vascular diseases.
• Diabetes and Endocrinology Medications Diabetes and endocrinology treatments including Sitagliptin/Ravidaglin, Vildagliptin/Vilmitrix, Vildagliptin+Metformin/Vilmitrix MET, and Cinacalcet/Cinatipar supplied to hospitals and endocrinology centers.
• MRI Contrast Agents Diagnostic imaging agents including Gadobutrol/Gadobutrol-TL and Gadoteric acid/Gadotheric acid-TL for magnetic resonance imaging, used in hospitals and diagnostic centers.
• Radiotherapy Linear Accelerators Medical linear accelerators (including TrueBeam Accelerator, Edge Radiosurgery System) and brachytherapy equipment (GammaMedplus iX) for radiation therapy, manufactured at R-Pharm's Radiotherapy Equipment Factory in Dubna under Varian technology.
• Contract Manufacturing and Technology Transfer Contract manufacturing services including technology transfer and license agreement manufacturing for international pharmaceutical and biotechnology companies from Japan, Korea, USA, Belgium, Germany, Switzerland, and Great Britain, leveraging R-Pharm's 11 GMP-certified plants.
• Medical Equipment Distribution Authorized distribution and localization of medical equipment and laboratory devices from Canon Medical Systems, Fujifilm, Varian Medical Systems, BD, Bio-Rad, Snibe, Lituo, Amplitek, PHC Europe B.V., and Astec Bio in the Russian market.

Quantifiable outcome

• Market launch of direct antiviral drug for hepatitis C treatment in 2016
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered core, major and standard.

• TRPharmcoreStrategic or Co-development Partner · 13 March 2024Partnership announced March 2024 for development of original medicine for treatment of Familial Mediterranean Fever in Turkey.
• Federal Research Center of the Russian Academy of SciencesmajorStrategic or Co-development Partner · 22 December 2022Partnership for development of drug for treatment of depression and neurodegenerative diseases announced December 2022.
• Frontier BiotechmajorStrategic or Co-development Partner · 13 July 2021Agreement to provide Russia with new drug for treatment of HIV through Frontier Biotech partnership.
• PHC Europe B.V.standardChannel Partner/ Reseller/ Distributor · 9 June 2021Distribution agreement signed June 2021 for medical equipment products.
• Astec BiostandardChannel Partner/ Reseller/ Distributor · 8 June 2021Agreement to commercialize EC6S-230MD flatbed incubator for in vitro fertilization procedures signed June 2021.
• AstraZenecacoreStrategic or Co-development Partner · 1 January 2021Clinical collaboration including development of Sputnik V and AstraZeneca vaccine combination study. R-Pharm developed clinical research program in partnership with AstraZeneca and Russian Direct Investment Fund (RDIF).
• Teva Pharmaceutical IndustriescoreStrategic or Co-development Partner · 1 January 2021Acquisition of TEVA's pharmaceutical plant in Yaroslavl (Russia) completed in 2021. New GMP-certified facilities expand production capacity for socially significant diseases.
• Belarus, Kazakhstan, Azerbaijan partnersmajorChannel Partner/ Reseller/ Distributor · 1 January 2019Joint projects launched in 2019 in Belarus, Kazakhstan and Azerbaijan including establishment of first pharmaceutical plant in Azerbaijan.
• EaptekastandardChannel Partner/ Reseller/ Distributor · 1 January 2019Joint purchase of stake in Eapteka online pharmacy with Sberbank in 2020 for expanded digital distribution.
• Canon Medical Systems CorporationcoreStrategic or Co-development Partner · 1 January 2018Large-scale partnership agreement signed in 2018 for medical equipment collaboration. In 2020, a joint venture agreement was concluded with Canon Medical Systems for healthcare technology initiatives.
• Fujifilm CorporationcoreStrategic or Co-development Partner · 1 January 2018Partnership agreement signed in 2018 for large-scale collaboration in the field of healthcare with Fujifilm medical systems and products.
• Varian Medical Systems, Inc.coreTechnology or Integration · 1 January 2018Acquisition of Radiotherapy Equipment Factory in 2018 for localization of Varian medical linear accelerators production in Russia. R-Pharm is authorized distributor of original Varian products including TrueBeam Accelerator, Edge Radiosurgery System, and GammaMedplus iX Brachytherapy Machine.
• R-Pharm Overseas, Inc. (with Alexey Repik)coreStrategic or Co-development Partner · 1 January 2011R-Pharm Overseas, Inc. founded in San Diego, USA in 2011 by Yan Lavrovsky and Alexey Repik for research activities and clinical trials capabilities.

Scale indicators14 records

Recent moves15 records

Expansion highlights7 records

Direct peers

• Pharmstandard: Pharmstandard is the largest Russian pharmaceutical manufacturer by sales, producing branded generics and originator drugs across cardiovascular, oncology, and infectious disease segments. It is the closest direct peer to R-Pharm in scale, therapeutic portfolio breadth, and Russia-centric distribution.
• Biocad: Biocad is a leading Russian biotech company developing and manufacturing monoclonal antibodies, biosimilars, and innovative biologics in oncology and autoimmune diseases. It directly competes with R-Pharm's Olokizumab and biosimilars (Rituximab, Bevacizumab, Pertuzumab) in Russian governmental tenders.
• Generium: Generium is a major Russian biotech focused on biosimilars, orphan drugs, and biologic drug substance manufacturing. It overlaps with R-Pharm on biosimilars and monoclonal antibody production and competes in similar hospital/government channels.
• Veropharm (Abbott Russia): Veropharm is a Russian pharmaceutical manufacturer producing generics and branded drugs across multiple therapeutic areas. Since acquisition by Abbott it remains a key domestic competitor in oncology, gastroenterology, and women's health.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer and a major player in biosimilars. R-Pharm acquired Teva's Yaroslavl plant in 2021, and Teva's portfolio, biosimilars pipeline, and ability to localize production for international markets make it a broad incumbent peer.
• AstraZeneca: AstraZeneca is a global biopharmaceutical leader in oncology, cardiovascular, and respiratory diseases. R-Pharm has a clinical collaboration with AstraZeneca on Sputnik V combination studies, and AZ ex-employees populate R-Pharm's leadership, making it a strategic partner-incumbent peer.
• Roche: Roche is a global leader in oncology biologics, immunology, and diagnostics. R-Pharm's biosimilars targeting Roche molecules (Rituximab, Bevacizumab, Pertuzumab) directly compete, positioning Roche as a broad incumbent peer with overlapping specialty therapeutics.
• Novartis: Novartis is a global pharmaceutical major in oncology, immunology, and cardiovascular. R-Pharm's CMO previously worked at Novartis, and Novartis's specialty care portfolio across oncology and autoimmune overlaps with R-Pharm's core R&D focus areas.

Emerging players

• Stada Arzneimittel: Stada is a European generics and specialty pharma company with significant operations in Russia/CIS. Its European specialty generics footprint and Russia presence make it a relevant emerging peer with partial product overlap in cardiovascular and immunology.

Regional players

• Polysan: Polysan is a Russian pharmaceutical company producing finished dosage forms across multiple therapeutic areas. It serves as a smaller-scale domestic competitor to R-Pharm in the Russian hospital and government procurement market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights8 records

Customer concentration

• Facebookfacebook.com/rpharmgroup

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about R-Pharm